Gewinn- und Verlustrechnung von Intuitive Surgical, Inc.

ISRG is expanding in Asia Pacific with a new Penang plant to boost capacity and support rising demand for robotic-assisted surgery.

Intuitive's revenue growth came in at 19% in its most recent quarter. The company's full-year guidance for procedures, however, was underwhelming and lower than the most recent quarter.

SpaceX seems promising, but the stock looks too expensive at current levels. Intuitive Surgical has lagged broader equities this year, but it's a great buy on the dip.

ISRG's software roadmap is strengthening da Vinci 5, with new features, renewals and recurring service revenues reinforcing its digital ecosystem.

Nvidia turns financier, CAVA's traffic sizzles, Berkshire ends its 3-year drought, and more

TBBB rallies on strong expansion, Anthropic could IPO with $2 trillion valuation, and more

ISRG's US procedure growth slows in Q2, but ACA-related care deferrals may prove temporary as underlying demand and da Vinci 5 adoption remain strong.

Intuitive Surgical is rated a Hold, with a modeled +9.17% upside and a price target of $426.65. ISRG's growth thesis centers on untapped ASC procedure volume, overstated remanufacturing risks, and remanufacturing's role in expanding the installed base. Remanufacturing currently poses a limited threat, with sub-3% penetration and approval for only 4 out of 45+ instruments.

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings page.

The stock may be down sharply, but don't count it out -- and the lower price makes it more attractive.